ARTICLES BY LOUIS

• Should You Search Globally For A CMO?

  9/21/2015

  I’m amazed in 2015 just the proposition of searching globally for CMOs is still a difficult decision for biotechs and other drug-developers. But because it is, I’ve captured some comments from industry experts at Outsourced Pharma West that may help.

• New-Era Drug Rx: C-Corp Per Compound And Large Dose Of Outsourcing

  9/14/2015

  Dauntless Pharmaceuticals isn’t the only company with a drug-development model based completely on outsourcing. Dauntless separates itself by where it takes the virtual-biotech model: It establishes a C-Corp for each compound it in-licenses. "From my management style, and viewpoint as a venture capitalist, this is how biotech should be done,” says Joel F. Martin, president and CEO.

• BioPharma Striving For LifeCycle Outsourcing™

  9/8/2015

  I’m usually pretty good at plucking overall themes from the various topics that swirl around international conferences. (Well, at least I think so.) That’s why initially failing to do so for the recent Outsourced Pharma West San Diego (OPW) conference was bothering me.

• Boxes At BMS: Impact Of New Drugs On Packaging Sponsors And Providers

  9/1/2015

  Packaging is transparent to the end-user when done well, but open to criticism from all quarters when done poorly. We can, though, expect an increasing amount of attention all the time. “There are more diverse packaging needs than ever before,” says Dan Marasco, head of Packaging Materials & Device Sourcing at Bristol-Myers Squibb.

• Physical Security For The Pharma Supply Chain

  8/20/2015

  Charles “Chuck” Forsaith quietly enters his Purdue Pharma office as the light of day lands on Stamford, Connecticut. For a little over an hour he pours over intelligence briefings on illicit drug activity around the globe. Sound like the start of a Tom Clancy novel? Rather, it’s the reality of a security professional charged with assessing supply-chain risk for pharmaceuticals.    

• Breaking Down Silos In The Field of Pharma

  8/14/2015

  Silos are as prevalent in the Pharma-related industries as anywhere else. But nearly 30 years after the term “functional silo syndrome” was coined, our medicine to get rid of silos may be equal parts as bad as the malady. The most recently announced attempt to reorganize out of silos — and into a more cross-functional approach — is at Catalent Pharma Solutions. 

• From J&J To Cognitive Psychology: Lifecycle Insights For Pharma

  8/6/2015

  William King was a career J&J executive who decided he had to leave the company. Ironically, it was so he could devote himself to solving a growing challenge there. “We had these important ‘lifecycle insights’ that we couldn’t take action on, despite having all these data points coming in,” says the CEO of Zephyr Healthcare. 

• Breaking News: Select Your CMO With Three (Well-Known) Attributes

  8/3/2015

  Here’s your news bulletin: Another experienced source goes on record sharing three basics to selecting the best CMO: credibility, work ethic, and relationships. “I gained experience and understanding of outsourcing from running our own CRO,” says Chris K. Achar, CEO of Genzum Life Sciences.

• BioPharma Fears CMO Capacity Crunch

  7/24/2015

  Fear is discernable in the voices of executives at BioPharma companies when considering a capacity crunch at CMOs. There’s also a rising resignation. Getting on CMO production schedules and securing commitments is a here-and-now challenge.

• Can This Outsourcing Model Save Health Care?

  7/15/2015

  A company has been formed to push aside the intermediaries standing between new drugs and the patients that need them. In the process, says Cynthia LaConte, CEO of Dohmen Life Science Services, this model of “intelligent outsourcing” will start to improve health care efficiencies and lower costs.